At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 175 enrolled
Drug / intervention
Gefapixant +1 moredrug
Likely dose
Gefapixant 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind Clinical Study to Evaluate the Long-term Safety and Efficacy of MK-7264 in Japanese Adult Participants With Refractory or Unexplained Chronic Cough
In Brief
A Phase 3 clinical trial evaluating Gefapixant and Placebo for Chronic Cough. Completed, enrolled 175 participants across 61 sites.
Detailed Summary
The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Cough
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2018
Primary CompletionOct 2020
TodayJul 2026
First PostedOct 4, 2018
Enrollment StartOct 31, 2018
Primary CompletionOct 7, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.7 years ago
Interventions
Gefapixantdrug
Gefapixant 15 mg or 45 mg tablet administered orally BID
Placebodrug
Placebo matched to gefapixant 15 mg or 45 mg administered orally BID